VEGFA and hematopoietic and lymphoid cell neoplasm: Using phosphosite-specific antibodies targeting different signal transduction pathways, such as the phosphoinositide 3-kinase (PI3 K), epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF) pathways, they were able to determine that the PI3K signaling pathway was up-regulated in different tumor types, and that the VEGF-angiogenesis pathway was down-regulated in hematopoietic cancers.